Boston Scientific Corporation BSX

Revenue Intelligence Report • 70 quarters of SEC filing data • Updated 2026-03-06

Boston Scientific Corporation continues to demonstrate strong revenue growth, with the latest quarterly revenue reaching $5,285 million, reflecting a robust demand for its medical devices. The company's strategic investment in Selling, General, and Administrative (SG&A) spending shows a compelling return on investment, generating $3.21 in long-run revenue for every dollar spent. With a solid model accuracy of 2.7% MAPE and a favorable holdout test prediction, the outlook for the fiscal year is promising, projecting a revenue increase of 13.3% year-over-year to $23 billion. Investors can remain confident in the company's trajectory, driven by effective spending and a strong market position.

Next FY Revenue

$22.75B

+13.3% YoY

SG&A Multiplier

$3.21 per $1

Model Accuracy

2.7% MAPE

Holdout validation: The model predicted $5B vs the actual $5B — an error of 0.2%.

Note: Boston Scientific Corporation does not report R&D expenses separately. This analysis uses SG&A spending only.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$5B	$5B	$5B – $5B	+15.7%	✓ In range
Q2 2026	$5B		$5B – $6B	+16.5%
Q3 2026	$6B		$5B – $6B	+10.7%
Q4 2026	$6B		$5B – $6B	+13.9%
Q1 2027	$6B		$5B – $6B	+12.4%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch